BRITSpA at five

Andrew Keat, Alexander N Bennett, Karl Gaffney, Gareth T Jones, Jane Martindale, Raj Sengupta, Stefan Siebert, Helena Marzo-Ortega

Research output: Contribution to journalEditorial

Abstract

It may seem that spondyloarthritis (SpA) has come of age, with new pathogenetic insights, valuable animal models and effective biologic therapies that have led to significant improvements in affected individuals. However, for all patients to receive the best care and for every research opportunity to be taken, clinicians and scientists in each country need to collaborate locally as well as internationally to ensure that innovations lead to the best possible care delivery within the context of each nation’s health services structure.
Original languageEnglish
Number of pages3
JournalRheumatology
Early online date9 Nov 2019
DOIs
Publication statusPublished - 9 Nov 2019

Fingerprint

Biological Therapy
Health Services
Animal Models
Research

Cite this

Keat, A., Bennett, A. N., Gaffney, K., Jones, G. T., Martindale, J., Sengupta, R., ... Marzo-Ortega, H. (2019). BRITSpA at five. Rheumatology. https://doi.org/10.1093/rheumatology/kez523

BRITSpA at five. / Keat, Andrew; Bennett, Alexander N; Gaffney, Karl; Jones, Gareth T; Martindale, Jane; Sengupta, Raj; Siebert, Stefan; Marzo-Ortega, Helena.

In: Rheumatology, 09.11.2019.

Research output: Contribution to journalEditorial

Keat, A, Bennett, AN, Gaffney, K, Jones, GT, Martindale, J, Sengupta, R, Siebert, S & Marzo-Ortega, H 2019, 'BRITSpA at five', Rheumatology. https://doi.org/10.1093/rheumatology/kez523
Keat A, Bennett AN, Gaffney K, Jones GT, Martindale J, Sengupta R et al. BRITSpA at five. Rheumatology. 2019 Nov 9. https://doi.org/10.1093/rheumatology/kez523
Keat, Andrew ; Bennett, Alexander N ; Gaffney, Karl ; Jones, Gareth T ; Martindale, Jane ; Sengupta, Raj ; Siebert, Stefan ; Marzo-Ortega, Helena. / BRITSpA at five. In: Rheumatology. 2019.
@article{6ee47aba071740fe82a0c95e8dae0098,
title = "BRITSpA at five",
abstract = "It may seem that spondyloarthritis (SpA) has come of age, with new pathogenetic insights, valuable animal models and effective biologic therapies that have led to significant improvements in affected individuals. However, for all patients to receive the best care and for every research opportunity to be taken, clinicians and scientists in each country need to collaborate locally as well as internationally to ensure that innovations lead to the best possible care delivery within the context of each nation’s health services structure.",
author = "Andrew Keat and Bennett, {Alexander N} and Karl Gaffney and Jones, {Gareth T} and Jane Martindale and Raj Sengupta and Stefan Siebert and Helena Marzo-Ortega",
note = "The authors would like to thank Dr Mohammad Derakhshan, BRITSpA Research Fellow (2016–2019) and Karly Graham, administrator. H.M.O. is supported by the NIHR Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the (UK) National Health Service (NHS), the NIHR or the (UK) Department of Health. Funding: No specific funding was received from any funding bodies in the public, commercial or not-forprofit sectors to carry out the work described in this manuscript.",
year = "2019",
month = "11",
day = "9",
doi = "10.1093/rheumatology/kez523",
language = "English",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "OXFORD UNIV PRESS INC",

}

TY - JOUR

T1 - BRITSpA at five

AU - Keat, Andrew

AU - Bennett, Alexander N

AU - Gaffney, Karl

AU - Jones, Gareth T

AU - Martindale, Jane

AU - Sengupta, Raj

AU - Siebert, Stefan

AU - Marzo-Ortega, Helena

N1 - The authors would like to thank Dr Mohammad Derakhshan, BRITSpA Research Fellow (2016–2019) and Karly Graham, administrator. H.M.O. is supported by the NIHR Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the (UK) National Health Service (NHS), the NIHR or the (UK) Department of Health. Funding: No specific funding was received from any funding bodies in the public, commercial or not-forprofit sectors to carry out the work described in this manuscript.

PY - 2019/11/9

Y1 - 2019/11/9

N2 - It may seem that spondyloarthritis (SpA) has come of age, with new pathogenetic insights, valuable animal models and effective biologic therapies that have led to significant improvements in affected individuals. However, for all patients to receive the best care and for every research opportunity to be taken, clinicians and scientists in each country need to collaborate locally as well as internationally to ensure that innovations lead to the best possible care delivery within the context of each nation’s health services structure.

AB - It may seem that spondyloarthritis (SpA) has come of age, with new pathogenetic insights, valuable animal models and effective biologic therapies that have led to significant improvements in affected individuals. However, for all patients to receive the best care and for every research opportunity to be taken, clinicians and scientists in each country need to collaborate locally as well as internationally to ensure that innovations lead to the best possible care delivery within the context of each nation’s health services structure.

UR - https://doi.org/10.1093/rheumatology/kez523

U2 - 10.1093/rheumatology/kez523

DO - 10.1093/rheumatology/kez523

M3 - Editorial

C2 - 31710687

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

ER -